Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 12/2007

01-12-2007 | Commentary

The enteroinsular axis may mediate the diabetogenic effects of TCF7L2 polymorphisms

Authors: M. A. Nauck, J. J. Meier

Published in: Diabetologia | Issue 12/2007

Login to get access

Excerpt

In an article in this issue of Diabetologia, Schäfer et al. report that the acute insulin response to glucagon-like peptide-1 (GLP-1) is reduced in individuals with normal or impaired oral glucose tolerance undergoing a hyperglycaemic clamp experiment [1]. This effect was specific for individuals with the polymorphisms rs7903146 or rs12255372 in the gene sequence coding for transcription factor 7-like-2 (TCF7L2), polymorphisms associated with an increased risk of type 2 diabetes [2‐4], and reduced insulin secretion [3, 5‐11]. TCF7L2 plays a role in the WNT signalling pathway [12], which (among other things) influences the synthesis (and possibly secretion) of GLP-1 [13], and the embryological development of the endocrine pancreas [14]. It was therefore of interest to characterise the effect of GLP-1 upon insulin secretion in individuals with these polymorphisms. …
Literature
1.
Schäfer SA, Tschritter O, Machicao F et al (2007) Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia, DOI 10.​1007/​s00125-007-0753-6
2.
Grant SF, Thorleifsson G, Reynisdottir I et al (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38:320–323PubMedCrossRef
3.
Florez JC, Jablonski KA, Bayley N et al (2006) TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 355:241–250PubMedCrossRef
4.
Wang J, Kuusisto J, Vänttinen M et al (2007) Variants of transcription factor 7-like 2 (TCF7L2) gene predict conversion to type 2 diabetes in the Finnish Diabetes Prevention Study and are associated with impaired glucose regulation and impaired insulin secretion. Diabetologia 50:1192–1200PubMedCrossRef
5.
Watanabe RM, Allayee H, Xiang AH et al (2007) Transcription factor 7–like 2 (TCF7L2) is associated with gestational diabetes mellitus and interacts with adiposity to alter insulin secretion in Mexican Americans. Diabetes 56:1481–1485PubMedCrossRef
6.
Saxena R, Gianniny L, Burtt NP et al (2006) Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 55:2890–2895PubMedCrossRef
7.
Loos RJ, Franks PW, Francis RW et al (2007) TCF7L2 polymorphisms modulate proinsulin levels and β-cell function in a British Europid population. Diabetes 56:1943–1947PubMedCrossRef
8.
Cauchi S, Meyre D, Choquet H et al (2006) TCF7L2 variation predicts hyperglycemia incidence in a French general population: the data from an epidemiological study on the Insulin Resistance Syndrome (DESIR) study. Diabetes 55:3189–3192PubMedCrossRef
9.
Chandak GR, Janipalli CS, Bhaskar S et al (2007) Common variants in the TCF7L2 gene are strongly associated with type 2 diabetes mellitus in the Indian population. Diabetologia 50:63–67PubMedCrossRef
10.
Marzi C, Huth C, Kolz M et al (2007) Variants of the transcription factor 7-like 2 gene (TCF7L2) are strongly associated with type 2 diabetes but not with the metabolic syndrome in the MONICA/KORA surveys. Horm Metab Res 39:46–52PubMedCrossRef
11.
Munoz J, Lok KH, Gower BA et al (2006) Polymorphism in the transcription factor 7-like 2 (TCF7L2) gene is associated with reduced insulin secretion in nondiabetic women. Diabetes 55:3630–3634PubMedCrossRef
12.
13.
Yi F, Brubaker PL, Jin T (2005) TCF-4 mediates cell-type-specific regulation of proglucagon gene expression by by β-catenin and glycogen synthase kinase-3β. J Biol Chem 280:1457–1464PubMedCrossRef
14.
Cauchi S, Meyre D, Dina C et al (2006) Transcription factor TCF7L2 genetic study in the French population: expression in human β-cells and adipose tissue and strong association with type 2 diabetes. Diabetes 55:2903–2908PubMedCrossRef
15.
Pilgaard K, Jensen CB, Poulsen P et al (2007) TCF7L2 is associated with reduced postprandial and postabsorptive insulin secretion, hyposecretion of glucagon, and impaired action of GLP-1 (abstract 70-OR). Diabetes 56(Suppl 1):A18
16.
Zeggini E, McCarthy MI (2007) TCF7L2: the biggest story in diabetes genetics since HLA? Diabetologia 50:1–4PubMedCrossRef
17.
Lyssenko V, Lupi R, Marchetti P et al (2007) Mechanism by which common variants in the TCF7L2 gene increase risk for type 2 diabetes. J Clin Invest 117:2155–2163PubMedCrossRef
18.
Toft-Nielsen MB, Damholt MB, Madsbad S et al (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717–3723PubMedCrossRef
19.
Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W (1993) Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7–36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76:912–917PubMedCrossRef
20.
Nauck MA, Homberger E, Siegel EG et al (1986) Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63:492–498PubMedCrossRef
21.
Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301–307PubMedCrossRef
22.
Vilsbøll T, Krarup T, Madsbad S, Holst JJ (2002) Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 45:1111–1119PubMedCrossRef
23.
Kjems LL, Holst JJ, Vølund A, Madsbad S (2003) The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52:380–386PubMedCrossRef
24.
Fritsche A, Stefan N, Hardt E, Häring H, Stumvoll M (2000) Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion. Diabetologia 43:852–858PubMedCrossRef
25.
Abraham EJ, Leech CA, Lin JC, Zulewski H, Habener JF (2002) Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology 143:3152–3161PubMedCrossRef
26.
Wang Q, Li L, Xu E, Wong V, Rhodes C, Brubaker PL (2004) Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 47:478–487PubMedCrossRef
27.
Farilla L, Bulotta A, Hirshberg B et al (2003) Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144:5149–5158PubMedCrossRef
28.
Fehmann H-C, Habener JF (1992) Insulinotropic hormone glucagon-like peptide-I (7–37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma (TC-1 cells. Endocrinology 130:159–166PubMedCrossRef
29.
Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC (1996) Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7–36) amide in patients with NIDDM. Diabetes 45:1524–15230PubMedCrossRef
30.
Quddusi S, Vahl TP, Hanson K, Prigeon RL, D’Alessio DA (2003) Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans. Diabetes Care 26:791–798PubMedCrossRef
31.
Holz GG, Kuhtreiber WM, Habener JF (1993) Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1 (7–37). Nature 361:362–365PubMedCrossRef
32.
Fehmann HC, Hering BJ, Wolf MJ et al (1995) The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets. Pancreas 11:196–200PubMedCrossRef
33.
Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696–1705PubMedCrossRef
Metadata
Title
The enteroinsular axis may mediate the diabetogenic effects of TCF7L2 polymorphisms
Authors
M. A. Nauck
J. J. Meier
Publication date
01-12-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 12/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0832-8

Other articles of this Issue 12/2007

Diabetologia 12/2007 Go to the issue

Article

Progesterone impairs cell respiration and suppresses a compensatory increase in glucose transport in isolated rat skeletal muscle: a non-genomic mechanism contributing to metabolic adaptation to late pregnancy?

Article

The effect of birth order and parental age on the risk of type 1 and 2 diabetes among young adults

Article

The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients

Letter

Increased physical activity is a cornerstone in the prevention of type 2 diabetes in high-risk individuals. Reply to Laaksonen DE, Lindström J, Tuomilehto J, Uusitupa M [letter]

Article

Brothers of women with polycystic ovary syndrome are characterised by impaired glucose tolerance, reduced insulin sensitivity and related metabolic defects

Article

Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits